RecruitingNot ApplicableNCT06989814

Smart Measurement of Circulating Tumor DNA

Smart Measurement of Circulating Tumor DNA: a Tumor-agnostic Computational Tool to Improve Colorectal Cancer Care

Sponsor

Erasmus Medical Center

Enrollment

50 participants

Start Date

May 16, 2025

Study Type

INTERVENTIONAL

Conditions

Colorectal Neoplasms Colorectal Neoplasms Malignant Colorectal Neoplasms, Hereditary Nonpolyposis Hereditary Nonpolyposis Colon Cancer

Summary

The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages. Participants will be asked to take an extra blood test, which will be analyzed further in the lab.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

(suspect) Lynch Syndrome carriers who:
Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor;
Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet;
Have granted informed consent to participate in this study.

Exclusion Criteria6

(suspect) Lynch Syndrome carriers who:
Are unwilling to undergo extra blood sampling;
Are under the age of 18;
Have no newly diagnosed tumors at time of inclusion;
Have been treated for their tumor at time of inclusion;
Are not able to read or understand Dutch language or are mentally not capable.

Interventions

DIAGNOSTIC_TESTBlood Product

An (extra) blood test will be done on participants. This will be analyzed for circulating tumor DNA (ctDNA) via a multi-omics approach.

Locations(2)

Leiden University Medical Center

Leiden, South Holland, Netherlands

Erasmus MC

Rotterdam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989814

Related Trials

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651383 locations

Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

NCT0729907113 locations